Seelos Therapeutics Inc (SEEL)

[OldtimeramI]

The question is, Why would a huge growing company like Allergan be interested in a small niche product like Vitaros, which they owned and did nothing with till Pascoe came knocking ? Is Allergan interested in DDAIP, Rayva, DDAIP and minoxidil ? Or did they just think what do they have to lose ?

If you think back on the timeline of this whole mess. Warner Chilcott was bought by Actavis. Then after that, Actavis and Allergan merged. How many selling drugs were they owners of? How many drug candidates in their combined pipepine? Do you really think that the people at Actavis and then Allergan know about Vitaros until you said it right - Richard Pascoe came knocking?

I doubt they knew about DDAIP either but does it matter? Do they not have enough drugs in their pipeline to not need DDAIP?

The tax write-off scenario? Well I guess I can entertain a scenario like that. But it doesn't have to be only Allergan. It can be any company willing to pay an amount for Apricus for tax benefits and a royalty on Vitaros.

For Apricus shareholders - Yes, they need a sale of the company. But what is $5 now? .50 cents pre reverse split. What's $10 now? $1 pre reverse split. We were here when Apricus' share price was $5. Which would be $50 now. No real value for whoever held on to their shares from our days.

So to answer your question. Yes, I think Allergan thought what do we have to lose? It was a win / win for both companies. They are not obligated to opt-in. Apricus paid Allergan whatever Warner Chilcott paid Apricus for the same rights - Apricus is doing the heavy lifting ( with the money of their shareholders ). And now if approved - Allergan can reap the rewards of a drug they never did any work on. If commercialized they get 20% royalties on a drug they probably didn't even know they had at a certain point.


By the way, and I'm only bringing this up as people here continue to focus on the positives and not on the possible negatives.

Are people aware that Majorelle is suing Apricus and Ferring?

A complaint was filed in the Supreme Court of the State of New York by Laboratoires Majorelle SAS and Majorelle International SARL on July 25, 2017 naming Apricus Biosciences, Inc., NexMed (U.S.A.), Inc. and Ferring International Center S.A. as defendants. The complaint seeks a declaratory judgment that a non-compete provision in a license agreement between us and Majorelle, dated November 12, 2013, is unenforceable and makes other claims relating to invalidity of our assignment of the license agreement to Ferring. The complaint also alleges breach of contract, fraudulent inducement, misrepresentation and unjust enrichment relating to a separate supply agreement between us and Majorelle. In addition to declaratory relief, Majorelle is seeking damages in excess of $1.0 million, punitive damages, disgorgement of profits and attorney’s fees. We believe the allegations are without merit, reject all claims raised by Majorelle and intend to vigorously defend this matter.

You think that Apricus won't dilute shareholders again if they have to pay Majorelle off? You have to remember that Majorelle was the partner that paid Apricus the most money for Vitaros rights. They paid off the whole FINESCO deal in France which Bassam Damaj got us in.

And yes, the more shares outstanding - the lower the possible sell price of the company per share.